AAAAAA

   
Results: 1-10 |
Results: 10

Authors: Ibrahim, NK Valero, V Rahman, Z Theriault, RL Walters, RS Buzdar, AU Booser, DJ Holmes, FA Murray, DJ Willey, J Bast, R Hortobagyi, GN
Citation: Nk. Ibrahim et al., Phase I-II vinorelbine (Navelbine((R))) by continuous infusion in patientswith metastatic breast cancer: Cumulative toxicities limit dose escalation, CANCER INV, 19(5), 2001, pp. 459-466

Authors: Holmes, FA Rowinsky, EK
Citation: Fa. Holmes et Ek. Rowinsky, Pharmacokinetic profiles of doxorubicin in combination with taxanes, SEMIN ONCOL, 28(4), 2001, pp. 8-14

Authors: Hortobagyi, GN Buzdar, AU Theriault, RL Valero, V Frye, D Booser, DJ Holmes, FA Giralt, S Khouri, I Andersson, B Gajewski, JL Rondon, G Smith, TL Singletary, SE Ames, FC Sneige, N Strom, EA McNeese, MD Deisseroth, AB Champlin, RE
Citation: Gn. Hortobagyi et al., Randomized trial of high-dose chemotherapy and blood cell autografts for high-risk primary breast carcinoma, J NAT CANC, 92(3), 2000, pp. 225-233

Authors: Esteva, FJ Soh, LT Holmes, FA Plunkett, W Meyers, CA Forman, AD Hortobagyi, GN
Citation: Fj. Esteva et al., Phase II trial and pharmacokinetic evaluation of cytosine arabinoside for leptomeningeal metastases from breast cancer, CANC CHEMOT, 46(5), 2000, pp. 382-386

Authors: Booser, DJ Walters, RS Holmes, FA Hortobagyi, GN
Citation: Dj. Booser et al., Continuous-infusion high-dose leucovorin with 5-fluorouracil and cisplatinfor relapsed metastatic breast cancer: A phase II study, AM J CL ONC, 23(1), 2000, pp. 40-41

Authors: Rivera, E Holmes, FA Frye, D Valero, V Theriault, RL Booser, D Walters, R Buzdar, AU Dhingra, K Fraschini, G Hortobagyi, GN
Citation: E. Rivera et al., Phase II study of paclitaxel in patients with metastatic breast carcinoma refractory to standard chemotherapy, CANCER, 89(11), 2000, pp. 2195-2201

Authors: Holmes, FA Valero, V Walters, RS Theriault, RL Booser, DJ Gibbs, H Fraschini, G Buzdar, AU Willey, J Frye, D Asmar, L Hortobagyi, GN
Citation: Fa. Holmes et al., Paclitaxel by 24-hour infusion with doxorubicin by 48-hour infusion as initial therapy for metastatic breast cancer: Phase I results, ANN ONCOL, 10(4), 1999, pp. 403-411

Authors: Berry, DL Theriault, RL Holmes, FA Parisi, VM Booser, DJ Singletary, SE Buzdar, AU Hortobagyi, GN
Citation: Dl. Berry et al., Management of breast cancer during pregnancy using a standardized protocol, J CL ONCOL, 17(3), 1999, pp. 855-861

Authors: Pusztai, L Holmes, FA Fraschini, G Hortobagyi, GN
Citation: L. Pusztai et al., Phase II study of mitoxantrone by 14-day continuous infusion with granulocyte colony stimulating factor (GCSF) support in patients with metastatic breast cancer and limited prior therapy, CANC CHEMOT, 43(1), 1999, pp. 86-91

Authors: Cristofanilli, M Holmes, FA Esparza, L Valero, V Buzdar, AU Neidhart, JA Hortobagyi, GN
Citation: M. Cristofanilli et al., Phase I II trial of high dose mitoxantrone in metastatic breast cancer: the M.D. Anderson Cancer Center experience, BREAST CANC, 54(3), 1999, pp. 225-233
Risultati: 1-10 |